Journal ArticleDOI
The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.
Paul E. Goss,S Qi,Robert G. Josse,Kenneth P.H. Pritzker,Kenneth P.H. Pritzker,M Mendes,H Hu,Stephen D. Waldman,Marc D. Grynpas,Marc D. Grynpas +9 more
Reads0
Chats0
TLDR
The positive results of EXE on bone and lipid metabolism in the OVX rat model merit further investigation of the effects of exemestane in postmenopausal women.About:
This article is published in Bone.The article was published on 2004-03-01. It has received 115 citations till now. The article focuses on the topics: Ovariectomized rat & Bone mineral.read more
Citations
More filters
Journal ArticleDOI
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Paul E. Goss,James N. Ingle,José E. Alés-Martínez,Angela M. Cheung,Rowan T. Chlebowski,Jean Wactawski-Wende,Anne McTiernan,John A Robbins,Karen C. Johnson,Lisa W. Martin,Eric Winquist,Gloria E. Sarto,Judy Garber,Carol J. Fabian,Pascal Pujol,Elizabeth Maunsell,Patricia L. Farmer,Karen A. Gelmon,Dongsheng Tu,Harriet Richardson +19 more
TL;DR: Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer and was associated with no serious toxic effects and only minimal changes in health-related quality of life.
Journal ArticleDOI
Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17
Edith A. Perez,Robert G. Josse,Kathleen I. Pritchard,James N. Ingle,Silvana Martino,B. Findlay,Tamara N. Shenkier,Richard Tozer,Michael J. Palmer,Lois E. Shepherd,Shifang Liu,Dongsheng Tu,Paul E. Goss +12 more
TL;DR: After 5 years of adjuvant tamoxifen, subsequent letrozole causes a modest increase in bone resorption and reduction in bone mineral density in the spine and hip compared to placebo.
Journal ArticleDOI
Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
Per Eystein Lønning,J. Geisler,Lars E. Krag,Bjørn Erikstein,Yngve Bremnes,Anne Irene Hagen,Ellen Schlichting,Ernst A. Lien,Erik S. Øfjord,Jolanda Paolini,Anna Polli,Giorgio Massimini +11 more
TL;DR: Exemestane modestly enhanced bone loss from the femoral neck without significant influence on lumbar bone loss, and no major effects on serum lipids, coagulation factors, or homocysteine were recorded.
Journal ArticleDOI
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
Paul E. Goss,James N. Ingle,Kathleen I. Pritchard,Matthew J. Ellis,George W. Sledge,G. Thomas Budd,Manuela Rabaglio,Rafat Ansari,David B. Johnson,Richard Tozer,David D'Souza,Haji Chalchal,Silvana Spadafora,Vered Stearns,Edith A. Perez,Pedro E.R. Liedke,István Láng,C. Elliott,Karen A. Gelmon,Judy Anne W. Chapman,Lois E. Shepherd +20 more
TL;DR: This first comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neither to be superior in terms of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two-way test.
Journal ArticleDOI
Cancer treatment-induced bone loss in breast and prostate cancer.
Fred Saad,Jonathan D. Adachi,Jacques P. Brown,Leah A. Canning,Karen A. Gelmon,Robert G. Josse,Kathleen I. Pritchard +6 more
TL;DR: Adjuvant endocrine therapy with an AI or androgen deprivation can be considered a risk factor for the development of osteopenia, osteoporosis, and bone fracture, which can be mitigated by appropriate bisphosphonate therapy.
References
More filters
Journal ArticleDOI
Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee
A. Michael Parfitt,Marc K. Drezner,Francis H. Glorieux,John A. Kanis,Hartmut H. Malluche,Pierre J. Meunier,Susan M. Ott,Robert R. Recker +7 more
TL;DR: A committee of the Society to develop a unified system of termnology, suitable for adoption by the Journal of Bone and Mineral Research as part of its Instructions to Authors is formed, and is as complex and conceptually difficult as the field with which it deals.
Journal ArticleDOI
Tamoxifen for early breast cancer: An overview of the randomised trials
TL;DR: The absolute improvement in recurrence was greater during the first 5 years, whereas the improvement in survival grew steadily larger throughout the first 10 years, and these benefits appeared to be largely irrespective of age, menopausal status, daily tamoxifen dose, and of whether chemotherapy had been given to both groups.
Journal Article
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group
TL;DR: There have been many randomised trials of adjuvant tamoxifen among women with early breast cancer, and an updated overview of their results is presented in this paper, which approximately doubles the amount of evidence from trials of about 5 years of tamoxifier and, taking all trials together, on events occurring more than 5 years after randomisation.
Journal Article
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
A. M. Parfitt,Marc K. Drezner,Francis H. Glorieux,John A. Kanis,Hartmut H. Malluche,P. J. Meunier,Susan M. Ott,Robert R. Recker +7 more
Journal Article
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
C. Focan,Seth M. Steinberg,M. Blichert-Toft,JF Forbes,Rory Collins,Stewart J. Anderson,R. Margreiter,C. S. Harwood,K. W. Andersen,G. Beighton,R. V. Borovik,EA Clarke,T Yasutomi,Walter Jonat,E. Mari,O. Abe,Richard Peto,Richard Gray,J. B. Vermorken,Bernard Asselain,Mitchell A Harris,Ingrid Tengrup,PC Lara,J.L. Laplanche,Sue Jackson,RJ Sylvester,H. Ueo,Pierre Fumoleau,R. Sauer,William C. Wood,Willi Sauerbrei,Rebecca Gelman,J. C. Redmond,Angelo Raffaele Bianco,Rodrigo Arriagada,M Hauer,Marie Overgaard,M. P. Cunningham,John L. Hayward,M. Kissin,Owen,W. Jack,Cooper,J. L. Pater,M. Ogawa,Jon Godwin,N Scorpiglione,Mike K. Palmer,H Johansen,H. Hayat,Aman U. Buzdar,Hyman B. Muss,H. Sonoo,David Riley,G. Brufman,MJ Piccart-Gebhart,John Bryant,R. Nissen,H. Koyama,J. Uchino,D. Parker,J Mace,M. Durand,G. Cocconi,Y. Morishita,CF Oliveira,R. L. Comis,A. Goldhirsch,M. Spielmann,J. E. Varhaug,Carsten Rose,J-B Bonte,A. R. Coates,C. S. McArdle,J. J. Price,Janet T. Powell,L. M. Vecchio,Martin Schumacher,Matthew Clarke,A. Nicolucci,Larry Norton,G. Mathe,H.H. Tooth,R. Huerta,A. Erazo Velásquez,Norman Wolmark,N. H. Gordon,Joan Houghton,Michael J. Baum,S. Gundersen,R. H. Creech,Gianni Bonadonna,D. C. Smith,R. J. Salmon,D.F. Hacking,R. C. Coombes,Kathleen I. Pritchard,Y. Lehingue,James J. Dignam,L. Mauriac,J. Myles,Sam Wieand,Spencer L. James,Carla I. Falkson,Carl Blomqvist,M. Belfiglio,H. L. Davis,AU Rubagotti,V. Gouon-Evans,K. Sawa,F. Pannuti,Francesco Boccardo,R. Abe,I.S. Fentiman,K. Sakai,T. M. Holdaway,Gloria Broadwater,Pinuccia Valagussa,M. G. Le,J. B. Dubois,Tae C Smith,J. Collins,M. Izuo,Manfred Kaufmann,C. K. Axelsson,Nancy E. Davidson,R Simon,AO de Lima,J. Yamashita,H. J. Trampisch,Jack Cuzick,S. Takashima,E. Robinson,G. Fountzilas,Lippman amp,Donna L. Berry,Henning T. Mouridsen,R. Wittes,A Kodric-Brown,R. M. Clark,D Jackson,N Corcoran,Umberto Veronesi,D. M. Dent,K Morimoto,C Davies,Y. Takatsuka,B Carstensen,Bernard Fisher,Lars-Gunnar Larsson,Cjh van de Velde,E. F. Lau,E. Greaves,P. Meier,Roger W. Blamey,John F. Forbes,Hma Yosef,R. Swindell,G. Bastert,Moïse Namer,JN Ingle,J. L. Misset,R. G. Kay,J. Benraadt,Christopher Hill,S. Romain,J. L. Haybittle,Karen N. Price,N. Wigler,R. Catalano,Judith M Bliss,Jfr Robertson,Lori J. Pierce,Vera J. Suman,Monica Castiglione,R D Rubens,H. Host,J. Albano,K. Kikuchi,A.J. Schauer,B. H. Mason,A Lewit-Bentley,Thierry Delozier,H.-J. Senn,Vilcoq,B Dil Blasio,T. Hakes,Douglass C. Tormey,J. Skolyszewski,K Welvaart,T. Tominaga,C. M. Rudenstam,JA Dongen,J. Costantino,S Bartholomeus,G. C. Mead,Michel Marty,Richard D. Gelber,M. Yoshida,McLaughlin,Mitch Levine,Joseph Ragaz,K. Enomoto,D Fournier,SB Schryver,V. J. Harvey,Udi Chetty,Y. Nomura,J. Lindtner,P. Forrest,N Cole Robert,Jacques Bonneterre,J. P. Lobelle,A. Bengry-Howell,P. Romestaing,I. C. Henderson,P Martin-Sanz,T. Palshof,G. C. Ribeiro,E Hannisdal,A. H. Gervasio,K. Sugimachi,Charles L. Shapiro,R. E. Crossley,C. Cirrincione,I. M. Jackson,Michael Gnant +226 more
TL;DR: The age-specific benefits of polychemotherapy appeared to be largely irrespective of menopausal status at presentation, oestrogen receptor status of the primary tumour, and of whether adjuvant tamoxifen had been given.
Related Papers (5)
A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.
R. C. Coombes,Emma Hall,Lorna Gibson,Robert Paridaens,Jacek Jassem,Thierry Delozier,Stephen E. Jones,Isabel Alvarez,Gianfilippo Bertelli,Olaf Ortmann,Alan S. Coates,Emilio Bajetta,D. Dodwell,Robert E. Coleman,Lesley Fallowfield,Elizabeth Mickiewicz,Jens O. Andersen,Per Eystein Lønning,G. Cocconi,Alan L Stewart,N Stuart,Claire Snowdon,M. Carpentieri,Giorgio Massimini,Judith M Bliss +24 more
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Paul E. Goss,James N. Ingle,Silvana Martino,Nicholas J. Robert,Hyman B. Muss,Martine Piccart,Monica Castiglione,Dongsheng Tu,Lois E. Shepherd,Kathleen I. Pritchard,Robert B. Livingston,Nancy E. Davidson,Larry Norton,Edith A. Perez,Jeffrey S. Abrams,Patrick Therasse,Michael Palmer,Joseph L. Pater +17 more